Report Information More information from: https ://www.wis eguyreports .com/reports /495853
Histamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016 Report / Search Code: WGR495853
Price
1-user P DF : $ 3500.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 7000.0
Enterprise P DF : $ 10500.0
His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Pipeline Review, H1 2016’, provides in depth analys is on His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted pipeline therapeutics . The report provides comprehens ive information on the His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105), targeted therapeutics , complete with analys is by indications , s tage of development, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics development and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape for His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - The report reviews His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics under development by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved in His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics and enlis ts all their major and minor projects - The report as s es s es His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics bas ed on mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news and deals related to His tamine H4 Receptor (H4R
or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) targeted therapeutics Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand the targeted therapy areas and indications for His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Identify the us e of drugs for target identification and drug repurpos ing - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) development lands cape - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 5 Introduction 6 Global Markets Direct Report Coverage 6 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) Overview 7 Therapeutics Development 8 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Products under Development by Stage of Development 8 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Products under Development by Therapy Area 9 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Products under Development by Indication 10 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Pipeline Products Glance 11 Late Stage Products 11 Early Stage Products 12 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Products under Development by Companies 13 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Therapeutics As s es s ment 15 As s es s ment by Monotherapy/Combination Products 15 As s es s ment by Mechanis m of Action 16 As s es s ment by Route of Adminis tration 18 As s es s ment by Molecule Type 20 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Companies Involved in Therapeutics Development 21 Chrys alis Pharma SAS 21 Griffin Dis coveries BV 22 Johns on & Johns on 23 OSE Pharma SA 24 Palau Pharma, S.A. 25 Sens orion S.A. 26 Z iarco Pharma Ltd 27 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or GPCR105) - Drug Profiles 28 GD-134 - Drug Profile 28 Product Des cription 28 Mechanis m Of Action 28 R& D Progres s 28 GD-136 - Drug Profile 29 Product Des cription 29 Mechanis m Of Action 29 R& D Progres s 29 GD-48 - Drug Profile 30 Product Des cription 30 Mechanis m Of Action 30 R& D Progres s 30 JNJ-28307474 - Drug Profile 31 Product Des cription 31 Mechanis m Of Action 31 R& D Progres s 31
or HRH4 or HRH4 or HRH4 or HRH4 or HRH4
or HRH4 or HRH4
or HRH4
or HRH4
JNJ-28610244 - Drug Profile 32 Product Des cription 32 Mechanis m Of Action 32 R& D Progres s 32 JNJ-40279486 - Drug Profile 33 Product Des cription 33 Mechanis m Of Action 33 R& D Progres s 33 SENS-218 - Drug Profile 34 Product Des cription 34 Mechanis m Of Action 34 R& D Progres s 34 Small Molecules to Agonize His tamine H4 Receptor for Cys tic Fibros is and Idiopathic Pulmonary Fibros is - Drug Profile 35 Product Des cription 35 Mechanis m Of Action 35 R& D Progres s 35 Small Molecules to Antagonize His tamine H1 and H4 Receptor for Ophthalmology and As thma - Drug Profile 36 Product Des cription 36 Mechanis m Of Action 36 R& D Progres s 36 Small Molecules to Antagonize His tamine H4 Receptor for Ves tibular Dis orders Drug Profile 37 Product Des cription 37 Mechanis m Of Action 37 R& D Progres s 37 toreforant tartrate - Drug Profile 38 Product Des cription 38 Mechanis m Of Action 38 R& D Progres s 38 tritoqualine - Drug Profile 40 Product Des cription 40 Mechanis m Of Action 40 R& D Progres s 40 UR-63325 - Drug Profile 41 Product Des cription 41 Mechanis m Of Action 41 R& D Progres s 41 Z PL-3893787 - Drug Profile 43 Product Des cription 43 Mechanis m Of Action 43 R& D Progres s 43 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dormant Projects 45 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Dis continued Products 48 His tamine H4 Receptor (H4R or AXOR35 or G-Protein Coupled Receptor 105 or HRH4 or GPCR105) - Featured News & Pres s Releas es 49 Feb 22, 2016: Sens orion Pres ents SENS-218 Data at As s ociation for Res earch in Otolaryngology Meeting 49 Feb 02, 2016: Phas e 2a Ps orias is Study Initiated with Z iarco Lead Compound Z PL389 50 Jan 06, 2016: Sens orion Receives Approval from the UK Drug Agency to Initiate Clinical Trial of SENS-218 50 Jun 10, 2015: Z iarco Initiates Phas e 2a Clinical Trial of Z PL-389 in Atopic Dermatitis 51 Apr 23, 2015: Sens orion s ucces s fully completes the firs t part of the clinical trial on SENS-111, which aims to treat s evere bouts of vertigo 52 Jun 18, 2014: Z iarco Secures £1.7M Grant from UK’s Technology Strategy Board to Support Phas e 2a of Z PL-389 in Atopic Dermatitis 53 Jun 08, 2010: Palau Pharma Reports Pos itive Firs t-In-Man Phas e I Clinical Trial Res ults For Its His tamine H4 Receptor Antagonis t UR-63325 53 Appendix 55 Methodology 55 Coverage 55 Secondary Res earch 55 Primary Res earch 55 Expert Panel Validation 55 Contact Us 55 Dis claimer 56 Lis t of Tables Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Indication, H1 2016 10 Comparative Analys is by Late Stage Development, H1 2016 11 Comparative Analys is by Early Stage Products , H1 2016 12 Number of Products under Development by Companies , H1 2016 13
Products under Development by Companies , H1 2016 14 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Stage and Mechanis m of Action, H1 2016 17 Number of Products by Stage and Route of Adminis tration, H1 2016 19 Number of Products by Stage and Molecule Type, H1 2016 20 Pipeline by Chrys alis Pharma SAS, H1 2016 21 Pipeline by Griffin Dis coveries BV, H1 2016 22 Pipeline by Johns on & Johns on, H1 2016 23 Pipeline by OSE Pharma SA, H1 2016 24 Pipeline by Palau Pharma, S.A., H1 2016 25 Pipeline by Sens orion S.A., H1 2016 26 Pipeline by Z iarco Pharma Ltd, H1 2016 27 Dormant Projects , H1 2016 45 Dormant Projects (Contd..1), H1 2016 46 Dormant Projects (Contd..2), H1 2016 47 Dis continued Products , H1 2016 48 Lis t of Figures Number of Products under Development for, H1 2016 8 Number of Products under Development by Therapy Area, H1 2016 9 Number of Products under Development by Top 10 Indication, H1 2016 10 Comparative Analys is by Early Stage Products , H1 2016 12 As s es s ment by Monotherapy/Combination Products , H1 2016 15 Number of Products by Mechanis m of Actions , H1 2016 16 Number of Products by Stage and Mechanis m of Actions , H1 2016 16 Number of Products by Routes of Adminis tration, H1 2016 18 Number of Products by Stage and Routes of Adminis tration, H1 2016 18 Number of Products by Stage and Molecule Type, H1 2016 20
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349